ClinicalTrials.gg
RecruitingNCT07631650Updated Nov 10, 2026

Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients

A Phase 2 interventional study of Bevonescein (ALM 488) Infusion in Head and Neck Disorder and Head and Neck Cancer, sponsored by Matthew Spector. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Matthew Spector · Phase 2, Interventional, and Treatment

How we know

Updated Nov 10, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,317 studies in Head and Neck Neoplasms with a site in United States — 187 open to participants now, 283 under way, 15 of them phase 3. Head and Neck Neoplasms · United States.

Planned enrollment
479th of 1,073
40 · median 36
Started
2026
with 57 others
Phase 2
354 of 1,317
42 open now
Primary completion
2027-11
later than 156 of 282 live
Registered
1,282nd of 1,317
by date

Among the 1,317 studies in Head and Neck Neoplasms with a site in United States, this one is the 479th largest by planned enrollment of the 1,073 interventional ones that give a count, is one of 58 that started in 2026, is one of 354 in phase 2, reaches primary completion later than 156 of the 282 other live ones, and was the 1,282nd registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

187 of the 1,317 studies in Head and Neck Neoplasms with a site in United States are open now. Recruiting first, the newest first:

181 more — sign in →

All 187 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,317 studies in Head and Neck Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Bevonescein (ALM-488) is a novel fluorescein-containing peptide that is intended as a visualization adjunct for the real-time enhanced structural delineation of major nerves during Head and Neck surgery to potentially improve patient outcomes.

Read the detailed description

Patients with thyroid disease undergoing thyroidectomy will receive systemic administration of bevonescein pre-operatively for intraoperative visualization of nerves. The voice outcomes of these patients will be assessed pre-operatively and post-operatively using patient questionnaires. This study aims to show that improved nerve visualization with bevonescein will be associated with clinically meaningful improvement in voice outcomes compared to a previously published studies.

03

Conditions studied

  • Head and Neck Disorder
  • Head and Neck Cancer

Keywords

  • vocal fold immobility
  • electromyographic (EMG) monitoring
  • thyroidectomy
  • intraoperative nerve visualization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Scheduled to undergo hemi thyroidectomy or total thyroidectomy for thyroid disease, including neoplasm
  2. Must be a minimum of 18 years old or older
  3. Must be able to give documented to participate in this study
  4. Must be a surgical candidate according to standard of care practices, as determined by the clinical judgement of the investigator
  5. Sexually active fertile subjects and their partners must agree to use highly effective methods of prior to study entry and during the course of the study. An additional contraceptive method, such as a barrier method (e.g., condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods.
  6. Female subjects of must not be pregnant or breastfeeding at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria is met:

    o Permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented status (defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of other biological or physiological causes). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.

  7. Willing and able to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  1. Previous history of surgery and/or radiation to the head, neck, or shoulder
  2. Abnormal cardiac rhythm not controlled with medication
  3. The patient has a history of drug-related anaphylactic or severe allergic reactions ( grade 3+), at the discretion of the treating investigator
  4. Presence or history of any to bevonescein (or fluorescein) or its that, in the judgment of the investigator, places the patient at increased risk for adverse effects
  5. Presence of a concurrent disease or condition that may interfere with study participation including recent (within 6 months of screening) Class III or IV heart failure, myocardial infarction (MI) or cerebrovascular accident (CVA)
  6. Presence or history of any condition that, in the view of the Investigator, places the patient at high risk of poor treatment compliance or of not completing the study
  7. Use of any Product or investigational medical device within 30 days prior to surgery date, or requirement for any investigational agent prior to completion of all scheduled study assessments
  8. The subject has current evidence of renal disease defined as (GFR) \< 60 mL/min/1.73 m2
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Bevonescein (ALM 488) Infusion

    Drug: Bevonescein (ALM 488) Infusion

Interventions

  • DrugBevonesceinStudies of BevonesceinBevonescein pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Bevonescein is a synthetic peptide of 17 amino acids conjugated to a fluorescein derivative (5-carboxyfluorescein \[FAM\]) and can be visualized using instruments suitable for visualizing fluorescein. Bevonescein selectively binds to extracellular matrix of nerve tissue, increasing nerve visibility and enhancing structure delineation of nerve tissue, potentially reducing the time needed for surgeons to identify nerve tissue and reducing likelihood of nerve injury during thyroidectomy surgery.

06

What researchers measure

Primary outcomes

  1. Change in Voice Handicap Index (VHI) scores

    Mean change in Voice Handicap Index (VHI) scores pre-operatively and post-operatively. Voice Handicap Index (VHI) is a 30-item self-administered questionnaire divided equally into three subscales designed to measure a patient's perceived handicap related to their voice disorder across functional, physical, and emotional domains. Functional (F) subscale (10 items) evaluates how voice problems affect daily activities, work, and social interactions (difficulty being understood on the phone or professional duty limitations). Physical (P) subscale (10 items) addresses physical sensations or characteristics of the voice problem (vocal fatigue, strain, or pitch changes). Emotional (E) subscale (10 items) assesses the emotional impact of a voice disorder (frustration, embarrassment, or anxiety) related to voice use. Item scores range from 0 (never) to 4 (always), with higher scores indicating a greater perceived handicap. Total VHI score: 0 to 120

    Time frame: At baseline (before surgery) and at 28 days post-surgery

Secondary outcomes

  1. Time to nerve identification In Thyroid Surgery

    Time to nerve identification after the superior pole vessels are taken down, which starts once the superior pole of the thyroid lobe is taken down and stops once the nerve is visualized and confirmed via nerve monitoring device per surgeon preference. In thyroidectomy, the superior pole vessels (typically the superior thyroid artery and its branches) are often dissected and mobilized before proceeding to the superior laryngeal nerve (SLN) identification. The SLN runs in close proximity to the superior thyroid artery, and thus removing the vessel can help expose the nerve and reduce the risk of injury. Earlier identification allows for protection of the nerve before further dissection.

    Time frame: Day of Surgery

  2. Visualization Scoring System (VSS) scores

    Visualization Scoring System (VSS) is completed during the surgery based on the surgeon's visual assessment using the REVEAL 475 system when viewing the surgical field and the recurrent laryngeal nerve. The REVEAL device and supportive illumination system consists of the TriBeam light source (designed to create a 3-inch spot of white or blue light) and filter-modified surgical loupes. The VSS assessment comprises of a 4-point Likert scale for Nerve Conspicuity (NC) and Branching Delineation of the nerve as compared to its surrounding tissue. NC scores: 1- 'None', 2- 'Weak', 3- 'Clear' and 4- 'Clear and Bright'. Branching Delineation scores: 1- 'None', 2- 'Poorly visible', 3- 'Sufficiently visible' Clear' and 4- 'Excellent visibility'. Total scores: 1 to 32. Higher scores mean better visualization.

    Time frame: Day of Surgery

  3. NERVE Questionnaire for Surgeons

    The NERVE questionnaire, consisting of 9 qualitative questions will be completed at the end of the surgical procedure by the surgeon. The questions measure the surgeon's perceived Confidence, Branching (ability to assess the nerve during the procedure), Discrimination (nerve distinction), Trajectory (ability to assess the nerve trajectory), Depth of penetration (ability to assess the nerve as it goes beyond the surgical surface) Convenience, Ease of use (of Bevonescein), Added value (added benefit/value towards nerve identification and/or localization for this patient) and Satisfaction overall. Possible responses to each question: Very satisfied, Satisfied, Somewhat satisfied, Neither satisfied nor dissatisfied, Somewhat dissatisfied, Dissatisfied, Very dissatisfied. No numerical scoring scale.

    Time frame: Day of Surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Nov 2027, 12 months after the start.

Of 219 non-industry phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 84. This study's planned 12 months is below that.

Counting every sponsor, half of 263 studies reached it within 51 months; a quarter within 30 and three quarters within 76.

Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Nov 10, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2027 → Nov 2027, on Nov 10, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2027 → Nov 2027, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 8, 2026
StartActual
Nov 4, 2026was Sep 2026
Primary completionEst.
Nov 4, 2027was Aug 2027
CompletionEst.
Nov 4, 2027was Aug 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 18, 2026→Nov 4, 2026 (actual)
moved 2 times, Oct 19, 2026 – Nov 10, 2026
Primary completion
Aug 31, 2027→Nov 4, 2027
Nov 10, 2026
Study completion
Aug 31, 2027→Nov 4, 2027
Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    Start date Oct 18, 2026→Nov 4, 2026 (now actual)
    Primary completion Aug 31, 2027→Nov 4, 2027
    Study completion Aug 31, 2027→Nov 4, 2027
    + 1 other change: verification date
  2. Oct 19, 2026
    Start date Sep 18, 2026→Oct 18, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07631650
Lead sponsor
Matthew Spector
Collaborators
Alume Biosciences, Inc.
Responsible party
Matthew Spector (Division Chief, Head & Neck Surgical Oncology & Microvascular Reconstruction, University of Pittsburgh) — Sponsor-investigator
First posted
Jun 8, 2026
Start date
Nov 4, 2026
Primary completion
Nov 4, 2027 (estimated)
Completion
Nov 4, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Jennifer Ruth
Contact
ruthj2@upmc.edu
412-623-8963
Mel J Mendez, BS, BS
Contact
mendezmj@upmc.edu
878-261-6071
Matthew E Spector
principal investigator · UPMC Hillman Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevonescein

Start the discussion